By Gilang Cahya 
In a groundbreaking development that sheds light on a perplexing modern medical mystery, an international consortium of scientists, spearheaded by researchers at the University of California San Diego, has identified a potent microbial agent – the bacterial toxin colibactin – as a likely driver behind the alarming surge in early-onset colorectal cancer. This discovery, published in the esteemed journal Nature, offers a crucial piece of the puzzle in understanding why an increasing number of individuals are being diagnosed with this disease at younger ages, often with no prior family history or discernible risk factors.
The Silent Invasion: Colibactin’s Genetic Imprint
Colibactin is a formidable weapon produced by specific strains of Escherichia coli, a bacterium commonly found residing within the human colon and rectum. Its sinister capability lies in its ability to directly damage and alter DNA. The new study reveals that exposure to colibactin, particularly during early childhood, leaves an indelible and distinct genetic signature on the DNA of colon cells. This molecular scar, researchers posit, significantly elevates the risk of developing colorectal cancer before the age of 50, a trend that has become increasingly prevalent and concerning globally.
The comprehensive analysis involved a deep dive into the genomes of 981 colorectal cancer patients, encompassing both early- and late-onset cases. This extensive dataset spanned 11 countries, representing a diverse spectrum of colorectal cancer incidence rates. The findings were stark: specific patterns of DNA mutations, directly attributable to colibactin, were found to be a staggering 3.3 times more common in early-onset cases – specifically among adults under 40 – compared to those diagnosed after the age of 70. Furthermore, these characteristic mutational signatures were disproportionately prevalent in countries that exhibit a higher incidence of early-onset colorectal cancer.
"These mutation patterns serve as a historical record within the genome, unequivocally pointing to early-life exposure to colibactin as a principal driving force behind early-onset disease," stated Ludmil Alexandrov, the study’s senior author and a distinguished professor at UC San Diego’s Shu Chien-Gene Lay Department of Bioengineering and Department of Cellular and Molecular Medicine. Professor Alexandrov, also affiliated with the UC San Diego Moores Cancer Center and Deputy Director of the Sanford Stem Cell Fitness and Space Medicine Center, emphasized the significance of this genetic evidence.
While prior research, including earlier work from Alexandrov’s laboratory, had hinted at the involvement of colibactin-related mutations in approximately 10 to 15 percent of all colorectal cancer cases, those studies were either limited to late-onset cases or failed to differentiate between early- and late-onset disease. This latest investigation marks a critical turning point, being the first to definitively demonstrate a substantial enrichment of colibactin-related mutations specifically within the demographic of early-onset colorectal cancer.
A Growing Epidemic Among the Young
The implications of these findings are profound and sobering. Colorectal cancer, once predominantly considered a disease of aging, is now witnessing an alarming upswing among younger populations in at least 27 countries worldwide. The incidence of this cancer in adults under the age of 50 has seen a near doubling every decade over the past two decades. Projections indicate that if current trends persist, colorectal cancer is poised to become the leading cause of cancer-related mortality among young adults by the year 2030, underscoring the urgency of understanding its underlying causes.
Historically, the reasons behind this escalating epidemic among the young have remained elusive. Young adults diagnosed with colorectal cancer often present without a family history of the disease and possess few, if any, of the traditionally recognized risk factors such as obesity, hypertension, or a sedentary lifestyle. This diagnostic conundrum has fueled speculation about the potential role of hitherto unrecognized environmental or microbial exposures, a hypothesis that this new study directly addresses.
Unraveling the Timeline of Damage
The journey to this discovery began with a broader objective. "When we initiated this project, our focus was not specifically on early-onset colorectal cancer," explained Marcos Díaz-Gay, a co-first author of the study and a former postdoctoral researcher in Alexandrov’s lab. "Our original aim was to investigate global patterns of colorectal cancer to ascertain why certain countries experience significantly higher rates than others. However, as we delved into the data, one of the most compelling and striking observations was the remarkable frequency with which colibactin-related mutations appeared in the early-onset cases."
Further molecular analysis by the research team has illuminated the insidious timeline of colibactin’s damaging effects. By precisely timing each identified mutational signature, the scientists have demonstrated that colibactin-associated mutations emerge early in the tumor development process. This finding aligns with previous studies that suggested such mutations can occur within the first decade of life. Crucially, the study also reveals that colibactin-related mutations are responsible for approximately 15 percent of what are known as APC driver mutations – a category of the earliest genetic alterations that directly promote cancer development – in colorectal cancer.
"If an individual acquires one of these driver mutations by the time they are 10 years old," Professor Alexandrov elaborated, "they could be decades ahead of the typical timeline for developing colorectal cancer, potentially experiencing a diagnosis at age 40 instead of the more common age of 60."
This suggests a concerning scenario where colibactin-producing bacteria may silently colonize the colons of children, initiating subtle yet significant molecular changes in their DNA. These early alterations could, in turn, lay the groundwork for the development of colorectal cancer long before any outward symptoms manifest, creating a hidden predisposition.
While the current findings provide robust evidence supporting this hypothesis, Professor Alexandrov cautioned that further rigorous research is essential to definitively establish causality and fully elucidate the intricate mechanisms at play.
A Legacy of Mutational Signature Analysis
This groundbreaking work is part of a larger, ambitious initiative known as Cancer Grand Challenges team Mutographs, generously funded by Cancer Research UK. It represents the latest milestone in an ongoing and expanding body of research championed by Professor Alexandrov, Dr. Díaz-Gay, and their colleagues over the past several years. Their collective expertise lies in the intricate art of deciphering the patterns of DNA mutations induced by various environmental exposures, including ultraviolet radiation and bacterial toxins, as well as lifestyle choices such as smoking and alcohol consumption. Each of these factors leaves a distinct genetic fingerprint on the genome – a unique mutational signature that serves as a crucial clue in pinpointing the origins of specific cancers.
Through a long-standing collaboration involving the University of California San Diego, the International Agency for Research on Cancer (IARC) in France, and the Wellcome Sanger Institute in the UK, made possible by Cancer Grand Challenges funding, the Mutographs team has successfully elucidated the mutational processes underlying several other major cancers globally, including esophageal, kidney, and head and neck cancers. The recent findings concerning colorectal cancer further broaden the global understanding of cancer etiology through the powerful lens of mutational signature analysis.
By systematically cataloging these distinct mutational patterns across thousands of cancer genomes, the researchers are actively engaged in identifying novel causes of cancer that have historically remained undetected or overlooked.
"Not every environmental factor or human behavior we investigate leaves a discernible mark on our genome," Professor Alexandrov observed. "However, we have discovered that colibactin is one such agent that demonstrably does. In this specific instance, its genetic imprint appears to be strongly correlated with colorectal cancers that develop in young adults."
Future Directions and Global Impact
The team’s latest discovery has ignited a cascade of new questions and avenues for future investigation. Paramount among these are the precise pathways through which children are exposed to colibactin-producing bacteria and the development of effective strategies to prevent or mitigate such exposure. Researchers are also keen to explore whether specific environmental conditions, dietary habits, or lifestyle choices might foster an environment more conducive to colibactin production. Furthermore, a critical question remains: how can individuals ascertain if they already harbor these colibactin-induced mutations?
The research team is actively pursuing several hypotheses to address these critical questions. Their ongoing work includes a deeper examination of the correlation between colibactin exposure and the risk of early-onset colorectal cancer. Additionally, they are exploring the potential therapeutic role of probiotics in safely eradicating harmful bacterial strains. A significant focus is also placed on developing innovative early detection tests that analyze stool samples for the presence of colibactin-related mutations, potentially enabling earlier intervention and improved patient outcomes.
Concurrently, the team is continuing its global quest to identify other cancer-linked mutational signatures. Their recent Nature publication also highlighted an increase in specific mutational signatures within colorectal cancers originating from particular countries, including Argentina, Brazil, Colombia, Russia, and Thailand. This observation strongly suggests that localized environmental exposures may also play a significant role in cancer risk, potentially contributing to regional disparities in disease incidence.
"It is entirely plausible that different countries harbor distinct, yet-to-be-identified causes of cancer," remarked Dr. Díaz-Gay, who is spearheading a new phase of the study from his recently established laboratory at the Spanish National Cancer Research Center (CNIO) in Madrid, Spain. "This realization opens up the exciting prospect of developing targeted, region-specific prevention strategies tailored to local environmental factors."
Professor Alexandrov underscored the broader, paradigm-shifting implication of this research: that a significant proportion of cancers may, in fact, originate from environmental or microbial exposures encountered in early life, long before any clinical diagnosis becomes possible.
"This discovery fundamentally reshapes our understanding of cancer," he concluded. "It suggests that cancer development may not solely be a consequence of events occurring in adulthood but could, in fact, be profoundly influenced by occurrences in early childhood, perhaps even during the very first few years of life. Sustained investment in this type of pioneering research is absolutely critical to our global efforts to prevent and effectively treat cancer before it becomes an insurmountable challenge."
